BioNTech

EQS-News: Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business

Retrieved on: 
Wednesday, April 10, 2024
Annual, Annual report, Tax, BioNTech, Coronavirus, Inflammation, Acquisition, Management, Dermatology, Depreciation, Pain, Growth, Parallel, Pharmaceutical industry

Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business

Key Points: 
  • Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business
    The issuer is solely responsible for the content of this announcement.
  • » Adjusted consolidated EBITDA margin: 27.3%
    Grünwald, 14 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its unaudited preliminary consolidated figures (IFRS) for financial year 2023.
  • Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) declined by 13.8% to EUR 310.2 million (prior-year period: EUR 359.8 million).
  • We exceeded our guidance for consolidated revenue and reached the upper end of the forecast range for adjusted EBITDA.

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Retrieved on: 
Sunday, April 7, 2024
BNTX, Survival, Entrepreneurship, Genentech, Disease, BioNTech, Patient, Neoplasm, Tissue, Messenger, PDAC, Roche, Uridine, Safety, Cancer, De novo, Recurrence, Blood, Vaccine

The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.

Key Points: 
  • The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.
  • The persistence of T cels was associated with a longer median recurrence-free survival in cancer vaccine responders.
  • “These new data are an early signal for the potential of our individualized mRNA cancer vaccine approach in this indication with an unmet medical need.
  • Over 80% of the vaccine-induced neoantigen-specific T cells could still be detected up to three years post administration in patients with an immune response.

Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Research, EUR, Ovarian cancer, Q&A, Partnership, BioNTech, Webcast, Patient, Co-stimulation, G&A, Synovial sarcoma, HLA, AACR, Clinical trial, Therapy, ESMO, Depreciation, Safety, TCR, Patent, Stomach, USD

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the fiscal year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the fiscal year ended December 31, 2023, and provided a corporate update.
  • General and administrative (G&A) expenses were EUR 9.3 million in 2023 compared to EUR 7.7 million in the year prior.
  • First pre-clinical data on MDG2011 was presented at the ESMO Congress 2023 and the SITC Annual Meeting 2023.
  • As of Dec 31, 2023, Medigene’s IP portfolio consisted of 112 issued and 131 pending patents across 28 patent families.

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, March 27, 2024
Malignancy, Colitis, Survival, BioNTech, Patient, Lung, City, Standard of care, Quality of life, Fungal infection, Aspergillosis, Nationwide, Clinical trial, Bone marrow, Melanoma, Aspergillus fumigatus, Therapy, Human, Psoriasis, Partnership, World Health Organization, Coccidioides, Safety, Clutch (eggs), University, Kidney, Amphotericin B, Neoplasm, Research, Data monitoring committee, Infection, Skin, Vanderbilt University Medical Center, Hospital, Immunodeficiency, FDA, Critical, Element, Toxicity, IL-17A, Brain, Conference call, Conference, Johns Hopkins, Nephrotoxicity, Docetaxel, Serum, Inflammation, Mouse, Mortality, Fusarium, Bangladesh Technical Education Board, Pharmaceutical industry

BEDMINSTER, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2023 financial results and provides a business update.

Key Points: 
  • Aspergillus fumigatus is also included in the FDA qualified designation list of pathogens that pose a serious and life-threatening risk.
  • Revenue for 2023 was $1.1 million, which was generated from the Company’s research collaborations with BioNTech SE and Genentech Inc.
  • Cash, cash equivalents and marketable securities as of December 31, 2023 were $13.8 million compared with $28.8 million as of December 31, 2022.
  • Matinas will host a conference call and webcast today beginning at 4:30 p.m. Eastern time.

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Retrieved on: 
Wednesday, March 20, 2024
Novartis, BNTX, Prostate cancer, Supervisory board, Survival, Science, BioNTech, COVID-19, Patient, Lung, Breast, Prostate, Cancer, Translation, Marketing, Development, Pharmaceutical industry

Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.

Key Points: 
  • Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
  • Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access.
  • I believe its COVID-19 vaccine will only be the beginning of a series of approved products to follow in the years to come,” said Annemarie Hanekamp, designated Chief Commercial Officer at BioNTech.
  • Annemarie Hanekamp is a Dutch citizen and holds degrees in biomedical sciences as well as organizational leadership.

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, March 14, 2024
Nucleus, Bone marrow, BCMA, BioNTech, B-ALL, Patient, ALL, SLE, Engineering, Minocycline, European Medicines Agency, Therapy, Research, Canadian Aviation Regulations, Flow cytometry, ASH, General counsel, Immunotherapy, SVP, EMA, Legal Affairs, Trial of the century, GMP, SME, BLA, Nature Communications, Development, UCL, Biologics license application, Multiple myeloma, MIA, University College London, Senior, TRBC, GD2, ASCO, FDA, CD19, Conference call, Conference, MAA, EHA, ADS, MHRA, T cell, ACS Chemical Biology, PDUFA, Autoimmune disease, Pharmaceutical industry

“For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.

Key Points: 
  • “For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.
  • In February 2024, Autolus promoted Dr. Chris Williams to Chief Business Officer and Alex Driggs to Senior Vice President, Legal Affairs and General Counsel.
  • Dr. Leiderman brings extensive transactional and financial expertise, and Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’ Board.
  • Financial Results for the Year Ended December 31, 2023

The Gross Law Firm Notifies BioNTech SE Investors of a Class Action Lawsuit and Upcoming Deadline – BNTX

Retrieved on: 
Tuesday, March 12, 2024
NEXT, BioNTech, Risk, COVID-19, BNTX, Pfizer–BioNTech COVID-19 vaccine, Fraud, Security (finance)

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of BioNTech SE.

Key Points: 
  • NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of BioNTech SE.
  • Shareholders who purchased shares of BNTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE (BNTX)

Retrieved on: 
Monday, March 11, 2024
Class Action Lawsuit, Professional Services, Legal, BNTX, COVID, Forecasting, Law, Pfizer, BioNTech, Risk, COVID-19, Defendant, News, The Company, Suite, Pfizer–BioNTech COVID-19 vaccine, Court, Pharmaceutical industry

The Law Offices of Frank R. Cruz reminds investors of the upcoming March 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX ) securities between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).

Key Points: 
  • The Law Offices of Frank R. Cruz reminds investors of the upcoming March 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX ) securities between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).
  • On this news, BioNTech’s stock price fell $13.81, or 7.5%, to close at $169.30 per share on August 8, 2022, thereby injuring investors.
  • On this news, BioNTech’s stock price fell $4.60, or 3.6%, to close at $123.60 per share on March 27, 2023.
  • Then, on November 16, 2023, BioNTech released its third quarter 2023 financial results, confirming that “[i]nventory write-downs by BioNTech’s collaboration partner Pfizer .

BNTX DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

Retrieved on: 
Sunday, March 10, 2024
Titan, Pfizer–BioNTech COVID-19 vaccine, Court, BioNTech, Class, Plaintiff, Pfizer, Risk, Advertising, COVID-19, BNTX

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BNTX DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX

Retrieved on: 
Monday, March 11, 2024
Titan, Pfizer–BioNTech COVID-19 vaccine, Court, BioNTech, Class, Pfizer, Risk, Advertising, COVID-19, BNTX

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.